Objective  To conduct a multi-dimensional quantitative evaluation of intravenous iron formulations, to provide a reference for drug selection in medical institutions and rational clinical drug use.

Methods  Based on the A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions (the 2nd edition), the quantitative evaluation of four intravenous iron formulations, including four originator drugs and five generic drugs were conducted across five dimensions: pharmaceutical properties, effectiveness, safety, economy, and others.

Results  Except for iron dextran generic drugs, all originator drugs and generic drugs of intravenous iron formulations included in the evaluation achieved an overall score of over 70 points. Among them, ferric carboxymaltose (Ferinject) obtained the highest overall score (79.45 points), demonstrating advantages in pharmaceutical characteristics, effectiveness and safety. In the dimension-specific comparison, iron sucrose (Aiyishu) ranked first in the economic dimension (10 points), while iron dextran (CosmoFer) topped the list in other attribute dimensions (8 points).

Conclusion  Except for iron dextran generic drugs, all evaluated originator drugs and generic drugs of intravenous iron formulations scored above 70 points, indicating that they can all be strongly recommended for intravenous iron supplementation. Among them, ferric carboxymaltose (Ferinject) is the preferred option. Based on the comprehensive evaluation results of intravenous iron formulations derived from the Guideline, this study provides a scientific basis for evaluating and selecting intravenous iron formulations, as well as their rational use in clinical practice.

1.马玉颖, 吴海, 杨铁虹. 缺铁性贫血药物的研究进展[J]. 空军军医大学学报, 2023, 44(12): 1225-1228. [Ma YY, Wu H, Yang TH. Research progress of drugs for iron deficiency anemia[J]. Journal of Air Force Medical University, 2023, 44(12): 1225-1228.] DOI: 10.13276/j.issn.2097-1656.

2.中华医学会血液学分会红细胞疾病（贫血）学组. 铁缺乏症和缺铁性贫血诊治和预防的多学科专家共识（2022年版）[J]. 中华医学杂志, 2022, 102(41): 3246-3256. DOI: 10.3760/cma.j.cn112137-20220621-01361.

3.Van Doren LSM, Boykin K, Taylor KJ, et al. Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions[J]. Am J Hematol, 2024, 99(7): 1338-1448. DOI: 10.1002/ajh.27220.

4.Auerbach M, Gafter-gvili A, Macdougall IC. Intravenous iron: a framework for changing the management of iron deficiency[J]. Lancet Haematol, 2020, 7(4): e342-e350. DOI: 10.1016/s2352-3026(19)30264-9.

5.中华医学会血液学分会红细胞疾病（贫血）学组. 静脉铁剂应用中国专家共识（2019年版）[J]. 中华血液学杂志, 2019, 40(5):358-362. [Red Blood Cell Diseases (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus on the application of intravenous iron (2019)[J]. Chinese Journal of Hematology, 2019, 40(5): 358-362.] DOI: 10.3760/cma.j.issn.0253-2727.2019.05.002.

6.邢质聪, 孙福东, 薛青霞, 等. 4种静脉铁剂治疗缺铁性贫血的快速卫生技术评估[J]. 药物流行病学杂志, 2024, 33(9): 1030-1043. [Xing ZC, Sun FD, Xue QX, et al. Four intravenous iron formulations in the treatment of iron deficiency anemia: a rapid health technology assessment[J]. Chinese Journal of Pharmacoepidemiology, 2024, 33(9): 1030-1043.] DOI: 10.12173/j.issn.1005-0698.202406030.

7.李正翔, 段蓉. 基于德尔菲法构建《医疗机构药品遴选指南》研究问题及药品遴选指标体系[J]. 中国医院药学杂志, 2020, 40(22): 2372-2376. [Li ZX, Duan R. Construction of research questions and drug selection index system of "Drug Selection Guideline for Medical Institutions" based on Delphi method[J]. Chinese Journal of Hospital Pharmacy, 2020, 40(22): 2372-2376.] DOI: 1013286/j.1001-5213.2020.22.17.

8.门鹏, 杨毅恒, 翟所迪, 等. 基于药品临床综合评价的医疗机构药品遴选方法研究[J]. 中国药学杂志, 2023, 58(21): 1983-1987. DOI: 10.11669/cpj.2023.21.011.

9.赵志刚, 董占军, 刘建平. 中国医疗机构药品评价与遴选快速指南（第二版）[J]. 医药导报, 2023, 42(4): 447-456. [Zhao ZG, Dong ZJ, Liu JP. A quick guideline for drug evaluation and selection in Chinese medical institutions (the second edition) [J]. Herald of Medicine, 2023, 42(4): 447-456.] DOI: 10.3870/j.issn.1004-0781.2023.04.001.

10.李六水, 陈静, 刘洋, 等. 基于中国医疗机构药品评价与遴选快速指南（第二版）的超短效胰岛素类似物多维度量化评价[J]. 中国循证医学杂志, 2024, 24(10): 1141-1148. [Li LS, Chen J, Liu Y, et al. Multi-dimensional quantitative evaluation of rapid-acting insulin analogues based on the quick guideline for drug evaluation and selection in Chinese medical institutions (the second edition)[J]. Chinese Journal of Evidence-Based Medicine, 2024, 24(10): 1141-1148.] DOI: 10.7507/1672-2531.202403100.

11.汤莹, 杜光, 孙秋雁. 缺铁性贫血临床药物治疗进展[J]. 中国医院药学杂志, 2022, 42(23): 2560-2566. [Tang Y, Du G, Sun QY. Progress in clinical application of drugs to the treatment of iron deficiency anemia[J]. Chinese Journal of Hospital Pharmacy, 2022, 42(23): 2560-2566.] DOI: 10.13286/j.1001-5213.2022.23.22.

12.National Center for Biotechnology Information. Iron sucrose in non-dialysis dependent (NDD-CKD) pediatric patients[EB/OL]. (2018-2-20) [2025-3-1]. https://clinicaltrials.gov/study/NCT00721188?cond=Iron%20Sucrose%20Injection&tab= results&rank=7.

13.Gupta DR, Larson DS, Thomsen LL, et al. Pharmacokinetics of iron isomaltoside 1 000 in patients with stage 5 chronic kidney disease on dialysis therapy[J]. J Drug Metab Toxicol, 2013, 4(3): 1-6. DOI: 10.4172/2157-7609.1000152.

14.Ikuta K, Shimura A, Terauchi M, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in Japanese volunteers with iron-deficiency anemia[J]. Int J Hematol, 2018, 107(5): 519-527. DOI: 10.1007/s12185-018-2400-z.

15.国家心血管病中心, 国家心血管病专家委员会心力衰竭专业委员会, 中国医师协会心力衰竭专业委员会, 等. 国家心力衰竭指南2023（精简版）[J]. 中国循环杂志, 2023, 38(12): 1207-1238. [National Center for Cardiovascular Diseases, China National Heart Failure Society, Chinese Heart Failure Association of Chinese Medical Doctor Association, et al. National heart failure guideline 2023 (Simplified Version)[J]. Chinese Circulation Journal, 2023, 38(12): 1207-1238.] DOI: 10.3969/j.issn.1000-3614.2023.12.001.

16.Kietaibl S, Ahmed A, Afshari A, et al. Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care[J]. Eur J Anaesthesiol, 2023, 40(4): 226-304. DOI: 10.1097/eja.0000000000001803.

17.中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20): 1463-1502. DOI: 10.3760/cma.j.cn112137-20210201-00309.

18.Pavord S, Daru J, Prasannan N, et al. UK guidelines on the management of iron deficiency in pregnancy[J]. Br J Haematol, 2019, 188(6): 819-830. DOI: 10.1111/bjh.16221.

19.中国临床肿瘤学会. 肿瘤相关性贫血临床实践指南2024[M]. 北京: 中国临床肿瘤学会, 2024: 1-67.

20.Leung TW, Damodaran P, Torres R, et al. Expert consensus on improving iron deficiency anemia management in obstetrics and gynecology in Asia[J]. Int J Gynaecol Obstet, 2023, 163(2): 495-509. DOI: 10.1002/ijgo.14804.

21.中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识（2018修订版） [J]. 中华肾脏病杂志, 2018, 34(11): 860-866. [Expert Group of Chinese Medical Association Nephrology Branch for diagnosis and treatment of renal anemia. Chinese expert consensus on diagnosis and treatment for renal anemia (2018 revision)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866.] DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012.

22.Ko CW, Siddique SM, Patel A, et al. AGA clinical practice guidelines on the gastrointestinal evaluation of iron deficiency anemia[J]. Gastroenterology, 2020, 159(3): 1085-1094. DOI: 10.1053/j.gastro.2020.06.046.

23.National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management[EB/OL]. (2021-11-24) [2024-01-15]. https://www.nice.org.uk/guidance/ng203.

24.黄媛, 苏娜, 李丹, 等. 不同静脉铁剂治疗贫血效果的网状Meta分析[J]. 临床药物治疗杂志, 2022, 20(12): 29-34. [Huang Y, Su N, Li D, et al. Network Meta-analysis of different intravenous irons in the treatment of anemia[J]. Clinical Medication Journal, 2022, 20(12): 29-34.] DOI: 10.3969/j.issn.1672-3384. 2022.12.006.

25.Shin HW, Go DY, Lee SW, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: a systematic review and Meta-analysis[J]. Medicine, 2021, 100(20): e24571. DOI: 10.1097/md.0000000000024571.

26.Rogozińska E, Daru J, Nicolaides M, et al. Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network Meta-analysis[J]. Lancet Haematol, 2021, 8(7): e503-e512. DOI: 10.1016/s2352-3026(21)00137-x.

27.Pollock RF, Muduma G. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment[J]. Expert Rev Hematol, 2019, 12(2): 129-136. DOI: 10.1080/17474086.2019.1575202.

28.丁少雪, 赵伊慧, 王婷, 等. 静脉滴注异麦芽糖酐铁治疗缺铁性贫血的疗效及安全性评估:单中心回顾性分析[J]. 中华血液学杂志, 2024, 45(2): 178-183. [Ding SX, Zhao YH, Wang T, et al. Evaluation of the efficacy and safety of intravenous infusion of ferric derisomaltose in the treatment of iron deficiency anemia: a single-center retrospective analysis[J]. Chinese Journal of Hematology, 2024, 45(2): 178-183.] DOI: 10.3760/cma.j.cn121090-20230718-00009.

29.National Center for Biotechnology Information. To assess the impact of ferric carboxymaltose compared with iron sucrose in Chinese subjects on correcting iron deficiency anaemia[EB/OL]. (2021-6-10) [2025-2-10]. https://clinicaltrials.gov/study/NCT03591406.